Anyone else have thoughts on this one? Too small for institutional money to dive into right now, but that seems to be the only reason this thing isn't closer to $8, the setup looks pretty perfect. Phase 2 data in gastroparesis is solid, and Phase 3 design is similar. We should see data by June/July and they have cash runway through October. Also, I've never heard a company so open about selling the company after the data readout. Am I missing something?
